Skip to content

Study · Not a test of the peptide alone · 2026

1 result

Semaglutide-Induced Atypical Pustular Drug Eruption: A Case Report.

Elliott DC, Veon FL, McBride JD, Levin J

Cureus7 Jan 2026

PMID41658769 (opens in a new tab)PMCIDPMC12880732 (opens in a new tab)DOI10.7759/cureus.101016 (opens in a new tab)PepBankPUB-41658769
Download PDFPubMedAsk about this study
Jump to 1 result

Summary

Glucagon-like peptide 1 (GLP-1) agonists continue to gain popularity in treating an increasing number of chronic conditions. As such, it is imperative that providers keep a vigilant eye on patients utilizing these medicines, monitoring for both known and novel side effects. Herein, we present the case of a patient who developed a rash with features characteristic of acute generalized exanthematous pustulosis (AGEP) one month after increasing her dose of semaglutide (Ozempic®). Her eruption occurred outside of the normal timeline for AGEP but had phenotypic and histopathologic findings consistent with this condition, emphasizing the need for providers to maintain a broad differential when assessing cutaneous eruptions. In addition, this case represents the need to do a thorough ingredient analysis when investigating new symptoms, as it was elucidated that her reaction was likely due to the excipient propylene glycol rather than the active ingredient in semaglutide (Ozempic®). The safety of patients using semaglutide requires close correlation of clinical presentation, histopathologic findings, and multidisciplinary collaboration with pharmacists.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Semaglutide.

  1. 01HumanNot a test of Semaglutide aloneCase report or seriesSafety outcome

    A patient developed an AGEP-like rash one month after a dose increase of semaglutide (Ozempic); the reaction was likely due to the excipient propylene glycol rather than the active ingredient.

    In plain wordsOne patient developed a pustular rash after a dose increase of Ozempic; the authors think the cause was an added ingredient, not semaglutide itself.

    Peptide
    Semaglutide
    Outcome
    IncreaseAtypical pustular eruption (AGEP-like) after semaglutide dose increase
    Study

    n = 1

    Outcome group
    Adverse events · Skin and wound

    Source sentences

    Summary
    Herein, we present the case of a patient who developed a rash with features characteristic of acute generalized exanthematous pustulosis (AGEP) one month after increasing her dose of semaglutide (Ozempic®).
    1 context sentence
    Summary · context
    it was elucidated that her reaction was likely due to the excipient propylene glycol rather than the active ingredient in semaglutide (Ozempic®)

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.